retatrutide shot A New Obesity Drug Delivered Surgery-Level Weight Loss in Clinical Trials Retatrutide Weight Loss Results:Trial Data

Matenchuk, B

Malignant melanoma pertains to an aggressive skin tumor with poor prognosis, with approximately 50% of patients harboring gain-of-function mutations in the BRAF gene

When starting retatrutide, its common to experience reduced appetite, feeling full sooner, and mild digestive changes

If injectable products are used in a clinical setting, they should follow safe injection practices

Protein recommendations should be adjusted for patients with kidney disease

Retatrutide is an investigational triple-agonist (GLP-1, GIP, and glucagon) with a half-life of roughly 6 days (Coskun et al., Cell Metabolism, 2022)